IP Verse

Pharmaceutical Compositions Comprising An S1P Modulator - EP3103448

The patent EP3103448 was granted to Novartis on Jul 3, 2019. The application was originally filed on Sep 25, 2007 under application number EP16176663A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3103448

NOVARTIS
Application Number
EP16176663A
Filing Date
Sep 25, 2007
Status
Granted And Under Opposition
May 31, 2019
Grant Date
Jul 3, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBApr 20, 2020KRAUS & LEDERER PARTGMBBWITHDRAWN
LABORATORIOS LICONSAApr 3, 2020SCHONWITHDRAWN
BLUEPHARMA INDUSTRIA FARMACEUTICAApr 2, 2020HAMM & WITTKOPPWITHDRAWN
KRKAMar 20, 2020HOEFER & PARTNERWITHDRAWN
KRKAMar 20, 2020HOEFER & PARTNER PATENTANWALTE MBBWITHDRAWN
STADA ARZNEIMITTELDec 11, 2019HAMM & WITTKOPPWITHDRAWN
ZENTIVADec 9, 2019GREINERWITHDRAWN
HELMJul 4, 2019HAMM & WITTKOPPWITHDRAWN

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0627406
DESCRIPTIONEP0778263
DESCRIPTIONEP1002792
DESCRIPTIONGB1548022
DESCRIPTIONWO0206268
DESCRIPTIONWO0218395
DESCRIPTIONWO2004089341
EXAMINATIONCN1524518
EXAMINATIONEP1201236
OPPOSITIONCN1524518
OPPOSITIONEP1201236
OPPOSITIONEP1661881
OPPOSITIONEP1760071
OPPOSITIONWO2004089341
OPPOSITIONWO2008037421
OTHEREP1195165
OTHEREP1661881
OTHERWO2004089341
SEARCHEP1195165
SEARCHEP1661881
SEARCHWO2004089341
SEARCHWO2005002559
SEARCHWO2005058295

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- "Chapter 6: Hilfsstoffe; Section 3.1: Zucker und Zuckeralkohole", Bauer, Kurt H.; Frömming, Karl-Heinz; Führer, Claus, Pharmazeutische Technologie, Georg Thieme verlag Stuttgart, (1993), page 160, ISBN 3136925041-
EXAMINATION- KIBBE H (EDITOR) ED - KIBBE A H (ED), "HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, CELLULOSE, MICROCRYSTALLINE", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, AMERICAN PHARMACEUTICAL ASSOC. [U.A.], WASHINGTON, DC; US, (20000101), ISBN 978-0-85369-381-9, pages 102 - 103, XP001544055-
EXAMINATION- Raymond C Rowe ET AL, "Handbook of Pharmaceutical Excipients, Sixth edition /Passage/", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090101), pages 3pp,222, 364, 424, 425, 679 - 703, ISBN 978-0-85369-792-3, XP055397596-
EXAMINATION- STEPHEN R BYRN ET AL, "Chemical reactivity in solid-state pharmaceuticals: formulation implications", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 48, no. 1, doi:10.1016/S0169-409X(01)00102-8, ISSN 0169-409X, (20010516), pages 115 - 136, (20010420), XP002628347
OPPOSITION- "4114- fingolimod", Maryadele J. O`Neil et al.,, The Merck Index An Encyclopedia of Chemicals, Drugs, and Biologicals, 15th Edition, The Royal society of Chemistry, (20130000), page 1pp, 748, XP055658329-
OPPOSITION- "7 - Füll-und Bindemittel für die Tablettierung", PETER SCHMIDT et al., Pharmazeutische Hilfsstoffe Eigenschaften, Anwendung und Handelsprodukte, Eschborn, Govi-Verlag, (20130000), page 2pp, IV, 26-27, 136, XP055658315-
OPPOSITION- "Cellulose, mikrokristalline", F. von Bruchhausen et al.,, Hagers Handbuch der Pharmazeutischen Praxis, 5. Auflage, Berlin, Springer-Verlag, (19930000), vol. 7, pages 3pp, 807 - 808, XP055658308-
OPPOSITION- F. AKI et al., "FTY720: A new kid on the block for transplant immunosuppression", Expert Opinion on Biological Therapy, (20030000), vol. 3, no. 4, pages 665 - 681, XP002323233-
OPPOSITION- James E.F. Reynolds et al.,, MARTINDALE The Extra Pharmacopoeia 29th Edition, London, The Pharmaceutical Press, (19890000), page 1pp, 1434, XP055658324-
OPPOSITION- KURT H. BAUER et al., Pharmazeutische Technologie, (19930000), page 160-
OPPOSITION- Loyd V. Allen et al.,, Remington The Science and Practice of Pharmacy 22nd Edition, London, Philadelphia, Pharmaceutical Press, (20130000), page 2pp, 1061, XP055658362-
OPPOSITION- Rudolf VOIGT, Pharmazeutische Technologie für Studium und Beruf, 7 Auflage, Berlin, Ullstein Mosby GmbH & Co. KG.,, (19930000), pages 2pp, 243 - 244, XP055658348-
OPPOSITION- "Tablets", Roop K Khar et al.,, Lachman/Lieberman`s The Theory and Practice of Industrial Pharmacy, 4th Edition, New Dehli, CBS Publishers & Distributors Pvt Ltd.,, (20130000), page 2pp, 455, XP055658339-
OPPOSITION- "Tabletten /Passage/", Kurt H. Bauer, Karl-Heinz Frömming, Claus Führer, Pharmazeutische Technologie, 5. Auflage, Stuttgart, Gustav Fischer Verlag, (19970000), page 2pp, 315, XP055658351-
OPPOSITION- URSULA SCHÖFFLING, Arzneiformenlehre Ein Lehrbuch der Galenik für Theorie und Praxis, Stuttgart, Deutscher Apotheker Verlag, (19980000), pages 1pp, 148-149 , 174 , 188 - 189, XP055658297-
OPPOSITION- STEPHEN R. BYRN et al., "Chemical reactivity in solid-state pharmaceuticals: Formulation implications", Adv. Drug Delivery Rev., (20010000), vol. 48, doi:10.1016/S0169-409X(01)00102-8, pages 115 - 136, XP002628347
OPPOSITION- L. KAPPOS et al., "Oral fingolimod (FTY720) for relapsing multiple sclerosis", The New England Journal of Medicine, (20060000), vol. 355, no. 11, pages 1124 - 1140, XP002525320
OTHER- "Kapitel 6 - Hilfsstoffe", Kurt H. BAUER et al., Pharmazeutische Technologie, Georg Thieme Verlag, (19930000), page 160, XP055452717-
OTHER- Raymond C Rowe, Paul J Sheskey, Marian E Quinn, Handbook of Pharmaceutical Excipients, Sixth edition, Pharmaceutical Press, (20090000), pages 3pp,222, 364, 424, 425, 679 - 703, ISBN 978-0-85369-792-3, XP055397596-
OTHER- Stephen R Byrn; Wei Xu; and Ann W Newman, "Chemical reactivity in solid-state pharmaceuticals: formulation implications", Adv. Drug Delivery Rev., (20010000), vol. 48, pages 115 - 136, XP002628347
SEARCH- BRINKMANN V ET AL, "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, (20021001), vol. 14, no. 5, ISSN 0952-7915, pages 569 - 575, XP004377409 [A] 1-3,7,10-17 * page 569 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents